Agent Promising for Refractory Colon Cancer (CME/CE)
(MedPage Today) — The novel nucleoside drug TAS-102 may boost survival in refractory metastatic colorectal cancer, a phase II trial showed.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com